GlobeNewswire Inc | Nov 9, 2020 08:00AM EST

November 09, 2020

AUSTIN, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Aspira Womens Health, Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, today announced the appointment ofSandraE. Brooks, MD, MBA to its Board of Directors. The addition of Dr. Brooks brings the Board composition to seven members with the majority now female.

Its a tremendous honor to welcome Dr. Brooks to our Board of Directors at this important phase in the evolution of Aspira Womens Health.Dr. Brooks brings a wealth of knowledge and experience as a gynecologic oncologist by training as well as an experienced physician executive.Her significant insights will be invaluable as we pursue larger healthcare systems and expand into other gynecologic diseases, stated Valerie Palmieri, President, and CEO of Aspira Womens Health.

AboutSandraE. Brooks, MD, MBADr. Brooks is Senior Vice President & Chief Medical Officer at Thomas Jefferson University Hospitals, Center City Division, and a Professor in the Department of Obstetrics and Gynecology, Sidney Kimmel Medical College. Dr. Brooks trained in Obstetrics and Gynecology at the Hospital of the University of Pennsylvania and in Gynecologic Oncology at the Brigham and Womens Hospital, Harvard Medical School, Dr. Brooks also served as Professor and Director of the Division of Gynecology Oncology at the University of Maryland for 10 years where in addition to clinical practice, and teaching trainees, her research focused on health services and cancer disparities. Dr. Brooks received her MBA in Medical Services Management at Johns Hopkins University before transitioning to physician executive roles in multi-site ambulatory and health system settings.

It is my absolute pleasure to be a board member of a companyfocused on improving womens lives,and has the potential to detect ovarian cancer risk in populations of women for whomestablished assays may less sensitive, stated Dr.SandraE. Brooks, Senior Vice President & Chief Medical Officer at Thomas Jefferson University Hospitals, Center City Division. I believe my skills and perspective will complement the team, and look forward to serving with the other talentedBoard members.

About Aspira Womens Health Inc.Aspira Womens Health, Inc. (formerly known as, Vermillion inc.,Nasdaq:VRML) is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.OVA1plus includes our FDA-cleared products, OVA1, and OVERAto detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXTMtesting offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research. The next generation of products in development are OVANEXTMand EndoCheckTM.Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577Arr@lifesciadvisors.com

Media Contact:Jaime AbrusciRx Medical DynamicsTel 646-599-8606 jabrusci@rxmedyn.com